---
$id: https://graph.org.ai/products/commodity/51322201
$type: Product
source: UNSPSC
code: "51322201"
title: "Ezetimibe"
class: "51322200"
classTitle: "Antihyperlipidemic and hypocholesterolemic azetidines and cyclohexanes and fluorobenzenes and furans"
family: "51320000"
familyTitle: "Antihyperlipidemic and hypocholesterolemic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Ezetimibe

**UNSPSC Code**: 51322201
**Class**: [Antihyperlipidemic and hypocholesterolemic azetidines and cyclohexanes and fluorobenzenes and furans](Antihyperlipidemic and hypocholesterolemic azetidines and cyclohexanes and fluorobenzenes and furans.mdx)
**Family**: [Antihyperlipidemic and hypocholesterolemic agents](../Antihyperlipidemic and hypocholesterolemic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an anti-lipidemic agent with the molecular formula C24H21F2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EOR26LQQ24, chemically known as 2-azetidinone, 1-(4-fluorophenyl)-3-((3s)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r,4s)- but generally known as ezetimibe, which bears US NIH Compound Identifier 150311. European Medicines Agency schedules Ezetimibe in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16430MIG. The term EZETIMIBE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules ezetimibe in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule ezetimibe under HS 29337900 and SITC 51561. As of Q4 2014, EZETIMIBE remains the US FDA Preferred Term for this commodity. Ezetimibe bears US NLM identifiers UMLS ID C1142985 and NCI Concept Code C47529. SMILES: Fc1ccc(N2C(C(CCC(O)c3ccc(F)cc3)C2=O)c2ccc(O)cc2)cc1.

